Laurent G.
- Country
- France
- Department
- Service d'Hématologie Clinique
Research Overview
- Phase I Study of ISB 2001 in Patients with Relapsed or Refractory Multiple Myeloma
- Phase 2 Study of Belantamab Mafodotin and Mezigdomide in Patients with Relapsed/Refractory Multiple Myeloma Following BCMA-Targeting CAR-T or Bispecific Antibody Therapy
- Phase 2, multicenter, open‑label study of extended‑dosing belantamab mafodotin in combination therapy for relapsed/refractory multiple myeloma
Data & Insights
Has run more than one trial at 173 of 309 partner sites.
Specializations
Multiple Myeloma Treatment Innovation
The investigator specializes in researching novel therapeutic approaches for multiple myeloma, with particular focus on evaluating emerging treatments like elranatamab, teclistamab, and iberdomide in comparison to established therapies.
- Novel therapeutic combinations
- Treatment efficacy evaluation
- Drug comparison studies
Disease Monitoring and Assessment
Expertise in studying advanced diagnostic and monitoring techniques, including minimal residual disease (MRD) detection and PET imaging methodologies for multiple myeloma progression assessment.
- MRD monitoring strategies
- Imaging techniques
- Disease progression markers
Patient-Specific Treatment Approaches
Focus on developing treatment strategies for specific patient populations, including newly diagnosed, transplant-eligible, elderly, and relapsed/refractory multiple myeloma patients.
- Age-specific protocols
- Transplant eligibility considerations
- Treatment adaptation strategies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.